Four years out from opening its doors, Xylocor Therapeutics Inc. closed a $17 million series A as it prepared to move lead candidate XC-001, a cardiovascular angiogenic gene therapy, into phase I in individuals with refractory angina who have no other treatment options. The round was co-led by Sofinnova Ventures and LSP (Life Sciences Partners).